Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 144 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $7.16 |
|---|---|
| 52-week range | $5.31 - $10.05 |
| 50-day moving average | $6.29 |
| 200-day moving average | $7.59 |
| Wall St. target price | $12.94 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.16 from 2021-05-28
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 14.74% |
| 3 months (2021-05-05) | -16.06% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Revenue TTM | $66.7 million |
|---|---|
| Gross profit TTM | $100.4 million |
| Return on assets TTM | -8.82% |
| Return on equity TTM | -56.21% |
| Profit margin | -90.87% |
| Book value | $2.25 |
| Market capitalisation | $356.6 million |
TTM: trailing 12 months
There are currently 6.6 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 0.2% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.
CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 862198.18417639). CytomX Therapeutics's SIR currently stands at 7.71. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 7710 shares are currently held short.
However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1233% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 123 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.
Find out more about how you can short CytomX Therapeutics stock.
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $5.31 up to $10.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6855. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, ImmunoGen, Inc.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
